Basic and translational concepts of immune-mediated glomerular diseases

Journal of the American Society of Nephrology

Volumn 23, Issue 3, 2012, Pages 381-399

  Couser, William G ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BASEMENT MEMBRANE; COMPLEMENT SYSTEM; EXPERIMENTAL MODEL; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE;

EID: 84857953534     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011030304     Document Type: Short Survey

References (295)

1. Nangaku M, Couser WG: Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin ExpNephrol 9: 183-191, 2005 (Pubitemid 41414116)
2. Ponticelli C, Coppo R, Salvadori M: Glomerular diseases and transplantation: Similarities in pathogenetic mechanisms and treatment options. Nephrol Dial Transplant 26: 35-41, 2011
3. Anders HJ: Toll-like receptors and danger signaling in kidney injury. J Am Soc Nephrol 21: 1270-1274, 2010
4. Anders HJ, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 22: 1007-1018, 2011
5. Rosin DL, Okusa MD: Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 22: 416-425, 2011
6. Gonçalves GM, Castoldi A, Braga TT, Câmara NO: New roles for innate immune response in acute and chronic kidney injuries. Scand J Immunol 73: 428-435, 2011
7. Pickering M, Cook HT: Complement and glomerular disease: New insights. Curr Opin Nephrol Hypertens 20: 271-277, 2011
8. Puri TS, Quigg RJ: The many effects of complement C3- and C5-binding proteins in renal injury. Semin Nephrol 27: 321-337, 2007 (Pubitemid 46802917)
9. Lesher AM, Song WC: Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 15: 663-675, 2010
10. Chen M, Daha MR, Kallenberg CG: The complement system in systemic autoimmune disease. J Autoimmun 34: J276-J286, 2010
11. Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, Trouw LA: Complement activation by (auto-) antibodies. Mol Immunol 48: 1656-1665, 2011
12. Schroeder HW Jr, Cavacini L: Structure and function of immunoglobulins. J Allergy Clin Immunol 125[Suppl 2]: S41-S52, 2010
13. Couser WG, Baker PJ, Adler S: Complement and the direct mediation of immune glomerular injury: A new perspective. Kidney Int 28: 879-890, 1985
14. Stevens MG, Van Poucke M, Peelman LJ, Rainard P, De Spiegeleer B, Rogiers C, Van de Walle GR, Duchateau L, Burvenich C: Anaphylatoxin C5a-induced toll-like receptor 4 signaling in bovine neutrophils. J Dairy Sci 94: 152-164, 2011
15. Dixon FJ, Feldman JD, Vazquez JJ: Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis. J Exp Med 113: 899-920, 1961
16. Wilson CB, Dixon FJ: Diagnosis of immunopathologic renal disease. Kidney Int 5: 389-401, 1974
17. Cochrane CG, Koffler D: Immune complex disease in experimental animals and man. Adv Immunol 16: 185-264, 1973
18. Van Damme BJ, Fleuren GJ, Bakker WW, Vernier RL, Hoedemaeker PJ: Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38: 502-510, 1978 (Pubitemid 8338244)
19. Couser WG, Steinmuller DR, Stilmant MM, Salant DJ, Lowenstein LM: Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 62: 1275-1287, 1978 (Pubitemid 9075757)
20. Adler SG, Wang H, Ward HJ, Cohen AH, Border WA: Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest 71: 487-499, 1983 (Pubitemid 13160794)
21. Ward HJ, Cohen AH, Border WA: In situ formation of subepithelial immune complexes in the rabbit glomerulus: Requirement of a cationic antigen. Nephron 36: 257-264, 1984 (Pubitemid 14192568)
22. Couser WG, Salant DJ: In situ immune complex formation and glomerular injury. Kidney Int 17: 1-13, 1980 (Pubitemid 10063506)
23. Couser WG: Mechanisms of glomerular injury in immune-complex disease. Kidney Int 28: 569-583, 1985
24. Salant DJ, Adler S, Darby C, Capparell NJ, Groggel GC, Feintzeig ID, Rennke HG, Dittmer JE: Influence of antigen distribution on the mediation of immunological glomerular injury. Kidney Int 27: 938-950, 1985 (Pubitemid 15035560)
25. Fries JW, Mendrick DL, Rennke HG: Determinants of immune complex-mediated glomerulonephritis. Kidney Int 34: 333-345, 1988
26. Wener MH, Mannik M: Mechanisms of immune deposit formation in renal glomeruli. Springer Semin Immunopathol 9: 219-235, 1986
27. Strom TB, Koulmanda M: Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 20: 1677-1680, 2009
28. Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL: Cell-mediated immune injury in the kidney: Acute nephritis induced in the rat by azobenzenearsonate. Kidney Int 45: 1044-1056, 1994 (Pubitemid 24234722)
29. Wu J, Hicks J, Borillo J, Glass WF 2nd, Lou YH: CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest 109: 517-524, 2002 (Pubitemid 34171783)
30. Kim AH, Markiewicz MA, Shaw AS: Newroles revealed for T cells and DCs in glomerulonephritis. JClin Invest 119: 1074-1076, 2009
31. Miossec P, Korn T, Kuchroo VK: Interleukin- 17 and type 17 helper T cells. N Engl J Med 361: 888-898, 2009
32. Turner JE, Paust HJ, Steinmetz OM, Panzer U: The Th17 immune response in renal inflammation. Kidney Int 77: 1070-1075, 2010
33. Kitching AR, Holdsworth SR: The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 22: 235-238, 2011
34. Steinmetz OM, Summers SA, Gan PY, Semple T, Holdsworth SR, Kitching AR: The Th17-defining transcription factor RORgt promotes glomerulonephritis. J Am Soc Nephrol 22: 472-483, 2011
35. Turner JE, Paust HJ, Steinmetz OM, Peters A, Riedel JH, Erhardt A, Wegscheid C, Velden J, Fehr S, Mittrücker HW, Tiegs G, Stahl RA, Panzer U: CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. J Am Soc Nephrol 21: 974-985, 2010
36. Abdulahad WH, Stegeman CA, Kallenberg CG: Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology (Carlton) 14: 26-32, 2009
37. Rodriguez-Iturbe B, Musser JM: The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 19: 1855-1864, 2008
38. Rodríguez-Iturbe B, Batsford S: Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71: 1094-1104, 2007 (Pubitemid 46809132)
39. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ: Post-streptococcal acute glomerulonephritis in children: Clinical features and pathogenesis. Pediatr Nephrol 26: 165-180, 2011
40. Beres SB, Sesso R, Pinto SW, Hoe NP, Porcella SF, Deleo FR, Musser JM: Genome sequence of a Lancefield group C Streptococcus zooepidemicus strain causing epidemic nephritis: New information about an old disease. PLoS ONE 3: e3026, 2008
41. Brodsky SV, Nadasdy T: Infection-related glomerulonephritis. Contrib Nephrol 169: 153-160, 2011
42. Edelstein CL, Bates WD: Subtypes of acute postinfectious glomerulonephritis: A clinicopathological correlation. Clin Nephrol 38: 311-317, 1992 (Pubitemid 23030781)
43. Sorger K, Gessler U, Hübner FK, Köhler H, Schulz W, Stühlinger W, Thoenes GH, Thoenes W: Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol 17: 114-128, 1982 (Pubitemid 12192454)
44. Luo YH, Chuang WJ, Wu JJ, Lin MT, Liu CC, Lin PY, Roan JN, Wong TW, Chen YL, Lin YS: Molecular mimicry between streptococcal pyrogenic exotoxin B and endothelial cells. Lab Invest 90: 1492-1506, 2010
45. Fujigaki Y, Nagase M, Kojima K, Yamamoto T, Hishida A: Glomerular handling of immune complex in the acute phase of active in situ immune complex glomerulonephritis employing cationized ferritin in rats. Ultrastructural localization of immune complex, complements and inflammatory cells. Virchows Arch 431: 53-61, 1997 (Pubitemid 27338603)
46. Fujigaki Y, Batsford SR, Bitter-Suermann D, Vogt A: Complement system promotes transfer of immune complex across glomerular filtration barrier. Lab Invest 72: 25-33, 1995
47. Nordstrand A, Norgren M, Holm SE: Pathogenic-mechanism-of acute post-streptococcal glomerulonephritis. Scand J Infect Dis 31: 523-537, 1999
48. Sesso RC, Ramos OL, Pereira AB: Detection of IgG-rheumatoid factor in sera of patients with acute poststreptococcal glomerulonephritis and its relationship with circulating immunecomplexes. Clin Nephrol 26: 55-60, 1986
49. Vilches AR, Williams DG: Persistent anti-DNA antibodies and DNA-anti-DNA complexes in post-streptococcal glomerulonephritis. Clin Nephrol 22: 97-101, 1984 (Pubitemid 14054429)
50. Ardiles LG, Valderrama G, Moya P, Mezzano SA: Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Clin Nephrol 47: 1-5, 1997 (Pubitemid 27052796)
51. Satoskar AA, Nadasdy G, Plaza JA, Sedmak D, Shidham G, Hebert L, Nadasdy T: Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol 1: 1179-1186, 2006
52. Nasr SH, Markowitz GS, Stokes MB, Said SM, Valeri AM, D'Agati VD: Acute postinfectious glomerulonephritis in the modern era: Experience with 86 adults and review of the literature. Medicine (Baltimore) 87: 21-32, 2008
53. D'Amico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24: 179-196, 2004
54. Tumlin JA, Madaio MP, Hennigar R: Idiopathic IgA nephropathy: Pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2: 1054-1061, 2007
55. Coppo R, Feehally J, Glassock RJ: IgA nephropathy at two score and one. Kidney Int 77: 181-186, 2010
56. Floege J: The pathogenesis of IgA nephropathy: What is new and how does it change therapeutic approaches? Am J Kidney Dis 58: 992-1004, 2011
57. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803, 2011
58. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S: Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 104: 172-182, 1993
59. Novak J, Julian BA, Tomana M, Mestecky J: IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28: 78-87, 2008
60. Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ: Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int 80: 79-87, 2011
61. Yu HH, Chu KH, Yang YH, Lee JH, Wang LC, Lin YT, Chiang BL: Genetics and immunopathogenesis of IgA nephropathy. Clin Rev Allergy Immunol 41: 198-213, 2011
62. Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J: O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 17: 1192-1199, 2006
63. Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y: Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol 2011: 639074, 2011
64. Barratt J, Eitner F, Feehally J, Floege J: Immune complex formation in IgA nephropathy: A case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transplant 24: 3620-3623, 2009
65. Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y: Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 9: 2048-2054, 1998 (Pubitemid 28482152)
66. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1805, 2011
67. Wang Y, Zhao MH, Zhang YK, Li XM, Wang HY: Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells. Clin Exp Immunol 136: 168-175, 2004 (Pubitemid 38437779)
68. Ballardie FW, Brenchley PE, Williams S, O'Donoghue DJ: Autoimmunity in IgA nephropathy. Lancet 2: 588-592, 1988
69. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
70. Mauer SM, Sutherland DE, Howard RJ, Fish AJ, Najarian JS, Michael AF: The glomerular mesangium. 3. Acute immune mesangial injury: A new model of glomerulonephritis. J Exp Med 137: 553-570, 1973
71. Yamamoto T, Wilson CB: Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 32: 514-525, 1987 (Pubitemid 17154741)
72. Yamamoto T, Wilson CB: Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol 138: 3758-3765, 1987 (Pubitemid 17078247)
73. Brandt J, Pippin J, Schulze M, Hänsch GM, Alpers CE, Johnson RJ, Gordon K, Couser WG: Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49: 335-343, 1996 (Pubitemid 26051821)
74. Floege J, Johnson RJ, Couser WG: Mesangial cells in the pathogenesis of progressive glomerular disease in animal models. Clin Investig 70: 857-864, 1992
75. Emancipator SN: Prospects and perspectives on IgA nephropathy from animal models. Contrib Nephrol 169: 126-152, 2011
76. Johnson RJ: The glomerular response to injury: Progression or resolution? Kidney Int 45: 1769-1782, 1994
77. Moura IC, Benhamou M, Launay P, Vrtovsnik F, Blank U, Monteiro RC: The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 28: 88-95, 2008
78. Monteiro RC: Role of IgA and IgA fc receptors in inflammation. J Clin Immunol 30: 1-9, 2010
79. Schlöndorff D, Banas B: The mesangial cell revisited: No cell is an island. J Am Soc Nephrol 20: 1179-1187, 2009
80. Coppo R, Amore A, Peruzzi L, Vergano L, Camilla R: Innate immunity and IgA nephropathy. J Nephrol 23: 626-632, 2010
81. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E: Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 31: 820-829, 1987 (Pubitemid 17025916)
82. Oortwijn BD, Eijgenraam JW, Rastaldi MP, Roos A, Daha MR, van Kooten C: The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol 28: 58-65, 2008
83. Cybulsky AV: Membranous nephropathy. Contrib Nephrol 169: 107-125, 2011
84. Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D: C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol 42: 373-380, 2008
85. Espinosa M, Ortega R, Gómez-Carrasco JM, López-Rubio F, López-Andreu M, López- Oliva MO, Aljama P: Mesangial C4d deposition: A new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 24: 886-891, 2009
86. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17: 1724-1734, 2006 (Pubitemid 43794676)
87. Sanders JS, Rutgers A, Stegeman CA, Kallenberg CG: Pulmonary-renal syndrome with a focus on anti-GBM disease. Semin Respir Crit Care Med 32: 328-334, 2011
88. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556, 2003 (Pubitemid 36706542)
89. Cochrane CG, Unanue ER, Dixon FJ: A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med 122: 99-116, 1965
90. Lerner RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126: 989- 1004, 1967
91. Hébert MJ, Takano T, Papayianni A, Rennke HG, Minto A, Salant DJ, Carroll MC, Brady HR: Acute nephrotoxic serum nephritis in complement knockout mice: Relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 13: 2799-2803, 1998 (Pubitemid 28479525)
92. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH: Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficientmice. Clin Exp Immunol 110: 403-409, 1997 (Pubitemid 27525271)
93. Zhao J, Yan Y, Cui Z, Yang R, Zhao MH: The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3 (IV)NC1 is associated with disease severity. Hum Immunol 70: 425-429, 2009
94. Cui Z, Zhao MH: Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 7: 697-705, 2011
95. Cui Z, Wang HY, Zhao MH: Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int 69: 894-899, 2006
96. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG: Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363: 343-354, 2010
97. Hudson BG: The molecular basis of Good-pasture and Alport syndromes: Beacons for the discovery of the collagen IV family. J Am Soc Nephrol 15: 2514-2527, 2004
98. Kalluri R, Cantley LG, Kerjaschki D, Neilson EG: Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. J Biol Chem 275: 20027-20032, 2000 (Pubitemid 30441611)
99. Bolton WK, Chen L, Hellmark T, Fox J, Wieslander J: Molecular mapping of the Goodpasture's epitope for glomerulonephritis. Trans Am Clin Climatol Assoc 116: 229-236, discussion 237-238, 2005
100. Bolton WK, Chen L, Hellmark T, Wieslander J, Fox JW: Epitope spreading and autoimmune glomerulonephritis in rats induced by a T cell epitope of Good pasture's antigen. J Am Soc Nephrol 16: 2657-2666, 2005
101. Rocklin RE, Lewis EJ, David JR: In vitro evidence for cellular hypersensitivity to glomerular- basement-membrane antigens in human glomerulonephritis. N Engl J Med 283: 497-501, 1970
102. Dixon FJ:What are sensitized cells doing in glomerulonephritis? N Engl J Med 283: 536-537, 1970
103. Merkel F, Kalluri R, Marx M, Enders U, Stevanovic S, Giegerich G, Neilson EG, Rammensee HG, Hudson BG, Weber M: Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. Kidney Int 49: 1127-1133, 1996 (Pubitemid 26122716)
104. Bolton WK, Tucker FL, Sturgill BC: New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity. Nonhumorally mediated glomerulonephritis in chickens. J Clin Invest 73: 1263-1276, 1984 (Pubitemid 14139520)
105. Bolton WK, Chandra M, Tyson TM, Kirkpatrick PR, Sadovnic MJ, Sturgill BC: Transfer of experimental glomerulonephritis in chickens bymononuclear cells. Kidney Int 34: 598-610, 1988
106. Tipping PG, Holdsworth SR: T cells in crescentic glomerulonephritis. J Am Soc Nephrol 17: 1253-1263, 2006 (Pubitemid 43673405)
107. Couser WG: Pathogenesis of glomerulonephritis: From chickens to humans. Nephron Physiol 112: 17-23, 2009
108. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR: IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 20: 980-989, 2009
109. Phelps RG, Rees AJ: The HLA complex in Goodpasture's disease: A model for analyzing susceptibility to autoimmunity. Kidney Int 56: 1638-1653, 1999 (Pubitemid 29518164)
110. Salama AD, Chaudhry AN, Holthaus KA, Mosley K, Kalluri R, Sayegh MH, Lechler RI, Pusey CD, Lightstone L: Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti- GBM) disease. Kidney Int 64: 1685-1694, 2003 (Pubitemid 37323697)
111. Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, Yuan CM: Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22: 1946-1952, 2011
112. Arends J, Wu J, Borillo J, Troung L, Zhou C, Vigneswaran N, Lou YH: T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 176: 1252-1258, 2006 (Pubitemid 43099730)
113. Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A: Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 20: 123-130, 2009
114. Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, Hammerich L, Panzer U, Kaden S, Quaggin SE, Floege J, Gröne HJ, Kurts C: Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 119: 1286-1297, 2009
115. Hochheiser K, Engel DR, Hammerich L, Heymann F, Knolle PA, Panzer U, Kurts C: Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria. J Am Soc Nephrol 22: 306-316, 2011
116. Sung SS, Bolton WK: T cells and dendritic cells in glomerular disease: The new glomerulotubular feedback loop. Kidney Int 77: 393-399, 2010
117. Lindic J, Vizjak A, Ferluga D, Kovac D, Ales A, Kveder R, Ponikvar R, Bren A: Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther Apher Dial 13: 278-281, 2009
118. Hecht N, Omoloja A, Witte D, Canessa L: Evolution of antiglomerular basement membrane glomerulonephritis into membranous glomerulonephritis. Pediatr Nephrol 23: 477-480, 2008
119. Stilmant MM, Bolton WK, Sturgill BC, Schmitt GW, Couser WG: Crescentic glomerulonephritis without immune deposits: Clinicopathologic features. Kidney Int 15: 184-195, 1979 (Pubitemid 10229493)
120. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318: 1651-1657, 1988
121. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM: Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21: 1628-1636, 2010
122. Rutgers A, Sanders JS, Stegeman CA, Kallenberg CG: Pauci-immune necrotizing glomerulonephritis. Rheum Dis Clin North Am 36: 559-572, 2010
123. Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DR, Jennette JC, Kallenberg CG, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts R: Granulomatosis with polyangiitis(Wegener's):An alternative name for Wegener's granulomatosis. J Am Soc Nephrol 22: 587-588, 2011
124. Falk RJ, Jennette JC: ANCA disease:Where is this field heading? J Am Soc Nephrol 21: 745-752, 2010
125. Jennette JC, Xiao H, Falk R, Gasim AM: Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol 169: 211-220, 2011
126. Chen M, Kallenberg CG: ANCA-associated vasculitides - advances in pathogenesis and treatment. Nat Rev Rheumatol 6: 653-664, 2010
127. Wilde B, van Paassen P, Witzke O, Tervaert JW: New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 79: 599-612, 2011
128. Flint J, Morgan MD, Savage CO: Pathogenesis of ANCA-associated vasculitis. Rheum Dis Clin North Am 36: 463-477, 2010
129. Radford DJ, Savage CO, Nash GB: Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 43: 1337-1345, 2000 (Pubitemid 30416318)
130. Nagao T, Matsumura M, Mabuchi A, Ishida- Okawara A, Koshio O, Nakayama T, Minamitani H, Suzuki K: Up-regulation of adhesion molecule expression in glomerular endothelial cells by anti-myeloperoxidase antibody. Nephrol Dial Transplant 22: 77-87, 2007 (Pubitemid 46050331)
131. van Rossum AP, Rarok AA, Huitema MG, Fassina G, Limburg PC, Kallenberg CG: Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti- PR3 antibodies. J Leukoc Biol 76: 1162-1170, 2004 (Pubitemid 39602952)
132. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87: 4115-4119, 1990 (Pubitemid 20217992)
133. Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, Gröne HJ, Brinkmann V, Jenne DE: Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15: 623-625, 2009
134. Bosch X: LAMPs and NETs in the pathogenesis of ANCA vasculitis. J Am Soc Nephrol 20: 1654-1656, 2009
135. Jerke U, Rolle S, Dittmar G, Bayat B, Santoso S, Sporbert A, Luft F, Kettritz R: Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation. J Biol Chem 286: 7070-7081, 2011
136. Summers SA, Steinmetz OM, Gan PY, Ooi JD, Odobasic D, Kitching AR, Holdsworth SR: Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis. Arthritis Rheum 63: 1124-1135, 2011
137. Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ: New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79: 1379-1387, 1987 (Pubitemid 17099642)
138. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002
139. Primo VC, Marusic S, Franklin CC, Goldmann WH, Achaval CG, Smith RN, Arnaout MA, Nikolic B: Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 159: 327-337, 2010
140. Schreiber A, Xiao H, Falk RJ, Jennette JC: Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by antimyeloperoxidase antibodies. J Am Soc Nephrol 17: 3355-3364, 2006 (Pubitemid 44865278)
141. Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D, Nourshargh S, Cook HT, Pusey CD: Experimental autoimmune vasculitis: An animalmodel of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 174: 1212-1220, 2009
142. Ruth AJ, Kitching AR, Kwan RY, Odobasic D, Ooi JD, Timoshanko JR, Hickey MJ, Holdsworth SR: Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J Am Soc Nephrol 17: 1940-1949, 2006 (Pubitemid 44036178)
143. Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, Falk RJ, Jennette JC: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 167: 39-45, 2005 (Pubitemid 40884768)
144. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170: 52-64, 2007 (Pubitemid 47339189)
145. Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P: Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 71: 646-654, 2007 (Pubitemid 46494558)
146. Van Timmeren MM, Chen M, Heeringa P: Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Nephrology (Carlton) 14: 16-25, 2009
147. Xing GQ, Chen M, LiuG, Heeringa P, Zhang JJ, Zheng X, e J, Kallenberg CG, Zhao MH: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 29: 282-291, 2009
148. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder-Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D:Molecularmimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14: 1088-1096, 2008
149. Pendergraft WF 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC, Falk RJ: Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10: 72-79, 2004 (Pubitemid 38524701)
150. Hewins P, Belmonte F, Charles Jennette J, Falk RJ, Preston GA: Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N. Autoimmunity 44: 98-106, 2011
151. Preston GA, Pendergraft WF 3rd, Falk RJ: New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: The theory of autoantigen complementarity. Curr Opin Nephrol Hypertens 14: 217-222, 2005 (Pubitemid 40685632)
152. Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, Hogan SL, Chin H, Moll S, Jennette JC, Falk RJ: Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J AmSocNephrol 19: 2421-2429, 2008
153. Chen M, Kallenberg CG, Zhao MH: ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol 5: 313-318, 2009
154. Bolton WK, Innes DJ Jr, Sturgill BC, Kaiser DL: T-cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathologic correlations. Kidney Int 32: 869-876, 1987 (Pubitemid 18015518)
155. Cunningham MA, Huang XR, Dowling JP, Tipping PG, Holdsworth SR: Prominence of cell-mediated immunity effectors in "pauciimmune" glomerulonephritis. J Am Soc Nephrol 10: 499-506, 1999 (Pubitemid 29117631)
156. Wilde B, Thewissen M, Damoiseaux J, van Paassen P, Witzke O, Tervaert JW: T cells in ANCA-associated vasculitis: What can we learn from lesional versus circulating T cells? Arthritis Res Ther 12: 204, 2010
157. Nogueira E, Hamour S, Sawant D, Henderson S, Mansfield N, Chavele KM, Pusey CD, Salama AD: Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 25: 2209-2217, 2010
158. King WJ, Brooks CJ, Holder R, Hughes P, Adu D, Savage CO: T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 112: 539-546, 1998 (Pubitemid 28267439)
159. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, KallenbergCG: T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 98: 448-453, 1994 (Pubitemid 24374730)
160. Yang J, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, Schmitz JL, Pressler BM, Jennette JC, Falk RJ, Preston GA: ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 74: 1159-1169, 2008
161. Gan PY, Steinmetz OM, Tan DS, O'Sullivan KM, Ooi JD, Iwakura Y, Kitching AR, Holdsworth SR: Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 21: 925-931, 2010
162. Chavele KM, Shukla D, Keteepe-Arachi T, Seidel JA, Fuchs D, Pusey CD, Salama AD: Regulation of my eloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: The role of Treg cells and tryptophan degradation. Arthritis Rheum62: 1539-1548, 2010
163. Chiang CK, Inagi R: Glomerular diseases: Genetic causes and future therapeutics. Nat Rev Nephrol 6: 539-554, 2010
164. Cao Y, Schmitz JL, Yang J, Hogan SL, Bunch D, Hu Y, Jennette CE, Berg EA, Arnett FC Jr, Jennette JC, Falk RJ, Preston GA: DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 22: 1161-1167, 2011
165. Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW: Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase- ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46: 253-262, 2005 (Pubitemid 41040353)
166. Nasr SH, D'Agati VD, Park HR, Sterman PL, Goyzueta JD, Dressler RM,
167. Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D'Agati VD, Markowitz GS: Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 4: 299-308, 2009
168. Markowitz GS, D'Agati VD: Classification of lupus nephritis. Curr Opin Nephrol Hypertens 18: 220-225, 2009
169. Bhinder S, Singh A, Majithia V: Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: Results of a 6-year retrospective analysis. Am J Med Sci 339: 230-232, 2010
170. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y: Systemic lupus erythematosus: One disease or many [published online ahead of print October 25, 2011]? Autoimmun Rev
171. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC: Pathogenesis of human systemic lupus erythematosus: Recent advances. Trends Mol Med 16: 47-57, 2010
172. Mortensen ES, Rekvig OP: Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20: 696-704, 2009
173. Davidson A, Aranow C: Lupus nephritis: Lessons from murine models. Nat Rev Rheumatol 6: 13-20, 2010
174. Mannik M, Merrill CE, Stamps LD, Wener MH: Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 30: 1495-1504, 2003 (Pubitemid 36835445)
175. Mielle JE, Rekvig OP, Van Der Vlag J, Fenton KA: Nephritoigenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 44: 373-383, 2011
176. Raz E, Brezis M, Rosenmann E, Eilat D: Anti- DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 142: 3076-3082, 1989 (Pubitemid 19129925)
177. Waldman M, Madaio MP: Pathogenic autoantibodies in lupus nephritis. Lupus 14: 19-24, 2005 (Pubitemid 40216063)
178. Yanase K, Madaio MP: Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J Autoimmun 24: 145-151, 2005
179. Yung S, Cheung KF, Zhang Q, Chan TM: Anti-ds DNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 21: 1912-1927, 2010
180. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan- Rivas S, Sellas-Fernandez A, Vilardell-Tarres M: DNase1 activity in systemic lupus erythematosus patients with and without nephropathy. Rheumatol Int 30: 1601-1604, 2010
181. Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ: Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol 17: 3365-3373, 2006 (Pubitemid 44865279)
182. Smith KD: Lupus nephritis: Toll the trigger! J Am Soc Nephrol 17: 3273-3275, 2006
183. Shen Y, Chen XW, Sun CY, Dai M, Yan YC, Yang CD: Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases. Lupus 19: 1195-1203, 2010
184. Pickering MC, Botto M: Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 6: 490-493, 2010
185. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J: Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 16: 701-707, 2010
186. Marston B, Looney RJ: Connective tissue diseases: Translating the effects of BAFF in SLE. Nat Rev Rheumatol 6: 503-504, 2010
187. Bao L, Quigg RJ: Complement in lupus nephritis: The good, the bad, and the unknown. Semin Nephrol 27: 69-80, 2007
188. Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22: 285-295, 2011
189. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S: The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63: 1076-1085, 2011
190. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK: Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 104: 345-355, 1999
191. Apostolidis SA, Crispín JC, Tsokos GC: IL-17-producing T cells in lupus nephritis. Lupus 20: 120-124, 2011
192. Sawla P, Hossain A, Hahn BH, Singh RP: Regulatory T cells in systemic lupus erythematosus. Role of peptide tolerance [published online ahead of print October 7, 2011]. Autoimmun Rev (2011), doi:10.1016/j.autrev. 2011.09.008
193. Strickland FM, Richardson BC: Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 41: 278-286, 2008
194. Vuong MT, Gunnarsson I, Lundberg S, Svenungsson E, Wramner L, Fernström A, Syvänen AC, Do LT, Jacobson SH, Padyukov L: Genetic risk factors in lupus nephritis and IgA nephropathy - no support of an overlap. PLoS ONE 5: e10559, 2010
195. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ: Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 16: 175-179, 2005 (Pubitemid 43073170)
196. Smith KD, Alpers CE: Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 14: 396-403, 2005 (Pubitemid 40863080)
197. Alpers CE, Smith KD: Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 17: 243-249, 2008 (Pubitemid 351535926)
198. Alchi B, Jayne D: Membranoproliferative glomerulonephritis. Pediatr Nephrol 25: 1409-1418, 2010
199. Vernon KA, Pickering MC, Cook T: Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease. Contrib Nephrol 169: 198-210, 2011
200. Coleman TH, Forristal J, Kosaka T, West CD: Inherited complement component deficiencies in membranoproliferative glomerulonephritis. Kidney Int 24: 681-690, 1983 (Pubitemid 14208766)
201. Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC: Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 5: 770-782, 2010
202. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465-470, 1993 (Pubitemid 23056436)
203. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, Davis C, Gretch DR: Renal manifestations of hepatitis C virus infection. Kidney Int 46: 1255-1263, 1994 (Pubitemid 24330702)
204. Charles ED, Dustin LB: Hepatitis C virus-induced cryoglobulinemia. Kidney Int 76: 818-824, 2009
205. Cacoub P, Ghillani P, Revelen R, Thibault V, Calvez V, Charlotte F, Musset L, Youinou P, Piette JC:Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 31: 598-603, 1999 (Pubitemid 29487679)
206. Saadoun D, Sadallah S, Trendelenburg M, Limal N, Sene D, Piette JC, Schifferli JA, Cacoub P: Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 145: 308-312, 2006 (Pubitemid 44060122)
207. McMurray RW: Hepatitis C-associated autoimmune disorders. Rheum Dis Clin North Am 24: 353-374, 1998
208. Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, Dammacco F: Nonenveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 133: 275-282, 2003 (Pubitemid 36918603)
209. Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F: Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25: 1237-1244, 1997 (Pubitemid 27199954)
210. Sansonno D, Tucci FA, Ghebrehiwet B, Lauletta G, Peerschke EI, Conteduca V, Russi S, Gatti P, Sansonno L, Dammacco F: Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol 183: 6013-6020, 2009
211. Allam R, Anders HJ: The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 20: 538-544, 2008
212. Robson MG: Toll-like receptors and renal disease. Nephron, Exp Nephrol 113: e1-e7, 2009
213. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlöndorff D, Anders HJ: Tolllike receptor-7modulates immune complex glomerulonephritis. J Am Soc Nephrol 17: 141-149, 2006
214. Mühlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE: Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int 65: 1214-1223, 2004 (Pubitemid 38406959)
215. Zhang S, Audard V, Fan Q, Pawlak A, Lang P, Sahali D: Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 169: 94-106, 2011
216. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G: Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445-453, 2007
217. DAgati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398-2411, 2011
218. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2: 556-560, 1974
219. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40: 453-460, 1991
220. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115-2121, 2010
221. Mauer SM, Hellerstein S, Cohn RA, Sibley RK, Vernier RL: Recurrence of steroidresponsive nephrotic syndrome after renal transplantation. J Pediatr 95: 261-264, 1979 (Pubitemid 9211114)
222. Ali AA, Wilson E, Moorhead JF, Amlot P, Abdulla A, Fernando ON, Dorman A, Sweny P: Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 58: 849-852, 1994 (Pubitemid 24329192)
223. Rea R, Smith C, Sandhu K, Kwan J, Tomson C: Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 416-417, 2001 (Pubitemid 32123939)
224. Liu Z, Blattner SM, Tu Y, Tisherman R, Wang JH, Rastaldi MP, Kretzler M, Wu C: Alphaactinin- 4 and CLP36 protein deficiencies contribute to podocyte defects in multiple human glomerulopathies. J Biol Chem 286: 30795-30805, 2011
225. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422-1426, 2010
226. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010
227. Friedman DJ, Kozlitina J, Genovese G, Prachi Jog P, Pollak MR: APOL1 genotype identifies African Americans at high risk of non-diabetic kidney disease in the Dallas Heart Study. J Am Soc Nephrol 22: 2129-2137, 2011
228. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129-2137, 2011
229. Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D'Agati VD, Klotman PE, Gharavi AG: APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22: 1991-1996, 2011
230. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011
231. Welch GI, Saleem MA: Podocyte cytoskeleton: Key to functioning glomerulus in health and disease. Nat Rev Nephrol 8: 14-21, 2012
232. Zhu L, Jiang R, Aoudjit L, Jones N, Takano T: Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 22: 1621-1630, 2011
233. Sistani L, Dunér F, Udumala S, Hultenby K, Uhlen M, Betsholtz C, Tryggvason K, Wernerson A, Patrakka J: Pdlim2 is a novel actin-regulating protein of podocyte foot processes. Kidney Int 80: 1045-1054, 2011
234. Fuchshofer R, Ullmann S, Zeilbeck LF, Baumann M, Junglas B, Tamm ER: Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury. Histochem Cell Biol 136: 301-319, 2011
235. Clement LC, Avila-Casado C, Macé C, Soria E, Bakker WW, Kersten S, Chugh SS: Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17: 117-122, 2011
236. Tain YL, Chen TY, Yang KD: Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome. Cytokine 21: 155-159, 2003
237. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC: Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10: 529-537, 1999 (Pubitemid 29117634)
238. Parry RG, Gillespie KM, Mathieson PW: Effects of type 2 cytokines on glomerular epithelial cells. Exp Nephrol 9: 275-283, 2001 (Pubitemid 32620212)
239. Van Den Berg JG, Aten J, Chand MA, Claessen N, Dijkink L, Wijdenes J, Lakkis FG, Weening JJ: Interleukin-4 and interleukin- 13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 11: 413-422, 2000 (Pubitemid 30115071)
240. Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, Jordan SC, Yap HK: Overexpression of interleukin-13 induces minimalchange- like nephropathy in rats. J Am Soc Nephrol 18: 1476-1485, 2007 (Pubitemid 46717514)
241. Sellier-Leclerc AL, Duval A, Riveron S, Macher MA, Deschenes G, Loirat C, Verpont MC, Peuchmaur M, Ronco P, Monteiro RC, Haddad E: A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 18: 2732-2739, 2007 (Pubitemid 47531200)
242. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113: 1390-1397, 2004 (Pubitemid 39071694)
243. Reiser J, Mundel P: Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome. J Am Soc Nephrol 15: 2246-2248, 2004 (Pubitemid 39159324)
244. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ: Urinary CD80 is elevated inminimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78: 296-302, 2010
245. Navarro-Munoz M, Ibernon M, Perez V, Ara J, Espinal A, Lopez D, Bonet J, Romero R: Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal change disease and focal segmental glomerulosclerosis in adult patients. Nephrol Dial Transplant 26: 3914-3923, 2011
246. Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH: Minimal change disease: A "two-hit" podocyte immune disorder? Pediatr Nephrol 26: 645-649, 2011
247. Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Wymer DT, Yamabe H, Mathieson PW, Saleem MA, Garin EH, Johnson RJ: Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-{kappa}B-dependent pathway [published online ahead of print May 26, 2011]. Nephrol Dial Transplant doi: 10.1093/ndt/gfr271
248. Smeets B, Kuppe C, Sicking EM, Fuss A, Jirak P, van Kuppevelt TH, Endlich K, Wetzels JF, Gröne HJ, Floege J, Moeller MJ: Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 22: 1262-1274, 2011
249. Ohse T, Vaughan MR, Kopp JB, Krofft RD, Marshall CB, Chang AM, Hudkins KL, Alpers CE, Pippin JW, Shankland SJ: De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am J Physiol Renal Physiol 298: F702-F711, 2010
250. Ronco P, Debiec H: Membranous glomerulopathy: The evolving story. Curr Opin Nephrol Hypertens 19: 254-259, 2010
251. Ronco P, Debiec H: Antigen identification in membranous nephropathy moves toward targetedmonitoring and newtherapy. J Am Soc Nephrol 21: 564-569, 2010
252. Kerjaschki D: Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 364: 1194-1196, 2004
253. Couser WG, Nangaku M: Cellular and molecular biology of membranous nephropathy. J Nephrol 19: 699-705, 2006 (Pubitemid 46415972)
254. Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 111: 877-885, 2003 (Pubitemid 37074963)
255. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM: Antenatal membranous glomerulonephritis due to antineutral endopeptidase antibodies. N Engl J Med 346: 2053-2060, 2002 (Pubitemid 34680597)
256. Ronco P, Debiec H: Target antigens and nephritogenic antibodies in membranous nephropathy: Of rats and men. Semin Immunopathol 29: 445-458, 2007 (Pubitemid 350077262)
257. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
258. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ: Anti-phospholipase A? receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286-1291, 2011
259. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, Ghiggeri GM: Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21: 507-519, 2010
260. Debiec H, Ronco P: PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364: 689-690, 2011
261. Groggel GC, Adler S, Rennke HG, Couser WG, Salant DJ: Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest 72: 1948-1957, 1983 (Pubitemid 14224400)
262. Couser WG, Ochi RF, Baker PJ, Schulze M, Campbell C, Johnson RJ: C6 depletion reduces proteinuria in experimental nephropathy induced by a nonglomerular antigen. J Am Soc Nephrol 2: 894-901, 1991
263. Couser WG, Stilmant MM, Jermanovich NB: Complement-independent nephrotoxic nephritis in the guinea pig. Kidney Int 11: 170- 180, 1977
264. Salant DJ, Madaio MP, Adler S, Stilmant MM, Couser WG: Altered glomerular permeability induced by F(ab')2 and Fab' antibodies to rat renal tubular epithelial antigen. Kidney Int 21: 36-43, 1982 (Pubitemid 12135746)
265. Salant DJ, Natori Y, Kawachi H: Glomerular injury due to antibody alone. In: Immunologic Renal Diseases, edited by Neilson EG, Couser WG, 2nd Ed., Philadelphia, Lippincott Wilkins, and Williams, 2001, pp 347-366
266. Leenaerts PL, Hall BM, Van Damme BJ, Daha MR, Vanrenterghem YF: Active Heymann nephritis in complement component C6 deficient rats. Kidney Int 47: 1604-1614, 1995
267. Spicer ST, Tran GT, Killingsworth MC, Carter N, Power DA, Paizis K, Boyd R, Hodgkinson SJ, Hall BM: Induction of passive Heymann nephritis in complement component 6-deficient PVG rats. J Immunol 179: 172-178, 2007 (Pubitemid 46986531)
268. Fervenza FC, Sethi S, Specks U: Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol 3: 905-919, 2008
269. Couser WG, Cattran D: Membranous nephropathy. In: Comprehensive Clinical Nephrology, edited by Johnson RJ, Feehally J, Floege J, London, Mosby International Publishers, 2010, pp 248-259
270. Ma H, Beck LH, Salant DJ: Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin complement pathway [abstract]. J Am Soc Nephrol 22: 62A, 2011
271. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández- Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathicmembranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
272. Pruchno CJ, Burns MM, Schulze M, Johnson RJ, Baker PJ, Alpers CE, Couser WG: Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis. Am J Pathol 138: 203-211, 1991
273. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG: Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 142: 179-187, 1993 (Pubitemid 23026921)
274. Glassock RJ: The pathogenesis of idiopathic membranous nephropathy: A 50-year odyssey. Am J Kidney Dis 56: 157-167, 2010
275. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
276. Penny MJ, Boyd RA, Hall BM: Role of T cells in the mediation of Heymann nephritis. ii. Identification of Th1 and cytotoxic cells in glomeruli. Kidney Int 51: 1059-1068, 1997 (Pubitemid 27186531)
277. Penny MJ, Boyd RA, Hall BM: Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis. J Exp Med 188: 1775-1784, 1998 (Pubitemid 28536765)
278. Couser WG, Stilmant MM, Darby C: Autologous immune complex nephropathy. I. Sequential study of immune complex deposition, ultrastructural changes, proteinuria, and alterations in glomerular sialoprotein. Lab Invest 34: 23-30, 1976
279. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616-626, 2011
280. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, Ronco P: Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl JMed 364: 2101-2110, 2011
281. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137-1143, 2011
282. Abrera MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ: Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22: 1551-1559, 2011
283. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD: Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4: 22-32, 2009
284. Smith RJ, Harris CL, Pickering MC: Dense deposit disease. Mol Immunol 48: 1604-1610, 2011
285. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F: Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193-199, 2007 (Pubitemid 46580528)
286. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC: C3 glomerulopathy: A new classification. Nat Rev Nephrol 6: 494-499, 2010
287. Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL: Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 9: 121-128, 1987 (Pubitemid 17042162)
288. Gale D, Pickering M: Regulating complement in the kidney. Insights from CFHR5 nephropathy. Dis Model Mech 4: 721-726, 2011
289. Strobel S, Zimmering M, Papp K, Prechl J, Józsi M: Anti-factor B autoantibody in dense deposit disease. Mol Immunol 47: 1476-1483, 2010
290. Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ: Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 75: 952-960, 2009
291. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ: Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6: 1009-1017, 2011
292. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31: 424-428, 2002 (Pubitemid 35154455)
293. Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ: Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22: 1551-1559, 2011
294. Gale DP, de Jorge EG, Cook HT, Martinez- Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC: Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376: 794-801, 2010
295. Rose KL, Paixao-Cavalcante D, Fish J, Manderson AP, Malik TH, Bygrave AE, Lin T, Sacks SH, Walport MJ, Cook HT, Botto M, Pickering MC: Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118: 608-618, 2008 (Pubitemid 351206550)